GlobalData Unmet Need for HIV Remains
- Novel HIV interventions needed to free patients from long-term ART
- Latest generation of ART 'could significantly threaten the adoption of novel curative treatments,' says analyst
Calls for Cures and Prevention of HIV, but Breakthroughs Still a Long Way Off, says GlobalData
LONDON, UK (GlobalData), 2 October 2013 - Despite the success of antiretroviral therapy (ART) in the treatment of HIV, a significant unmet need remains for the cure and prevention of the disease, although a number of challenges stand in the way of novel non-ART interventions, says the latest report from research and consulting firm GlobalData.
The new report* states that there is an ongoing need for interventions to control the HIV pandemic, including prophylactic vaccines, novel salvage therapies and an eventual cure for the condition, which will release patients from long-term ART.
Various efforts targeting different aspects of HIV are emerging, such as latency reversal agents and immunotherapies that educate the immune system to eliminate virus-infected cells. GlobalData now believes that the success of a functional cure could well come from an intervention which combines these approaches.
Dr. Charalampos Valmas, GlobalData’s Analyst covering Infectious Disease, says: “The need for new combinatorial therapies presents a unique opportunity for small biotech companies and academic laboratories to combine their forces, and we expect that the first successful regimen will attract Big Pharma, which could use its resources to conduct large-scale trials and market the therapy successfully.”
However, a number of significant barriers have presented themselves to new HIV treatments, including the fact that vaccine research and development (R&D) has at present been deprioritised by Big Pharma.
Valmas continues: “Big Pharma does not consider HIV or other STD vaccines as lucrative as those for airborne diseases, such as influenza, due to the limited patient segments that an HIV vaccine would initially address. As a result, research is instead being conducted by biotech companies, as well as academic and government-funded institutes, which sadly may not possess the financial capabilities to proceed to Phase III trials.”
Continuous improvements to ART will also have a strong impact on HIV R&D approaches towards a cure, as new regimens, such as integrase inhibitors, boast a much better safety profile.
“As integrase inhibitors are and will also be available as single-tablet regimens, therefore easing the dosage and increasing patient compliance, it is clear that this latest generation of ART could significantly threaten the adoption of novel curative treatments.
“It is therefore still a long way off before a functional non-ART cure or preventative vaccine for HIV will be available on the market,” concludes Valmas.
-NOTES TO EDITORS-
This report provides an overview of the latest advances in curative and preventative technologies for HIV, along with an analysis of the interplay between current therapeutic approaches and future curative ones. The key topics covered include unmet needs, opportunities, and drivers and barriers specific to preventative and therapeutic vaccines, latency reversal agents and gene therapies.
This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.
For guidelines on how to cite GlobalData, please see: http://www.globaldata.com/QuotingGlobalData.aspx
GlobalData is a leading global research and consulting firm offering advanced analytics to help clients make better, more informed decisions every day. Our research and analysis is based on the expert knowledge of over 700 qualified business analysts and 25,000 interviews conducted with industry insiders every year, enabling us to offer the most relevant, reliable and actionable strategic business intelligence available for a wide range of industries.
For more information, please contact our Press Office on +44 (0)1204 543 537 or at email@example.com.
Gain access to free expert analysis on the latest developments in your industry by connecting with us on:
Posted: October 2013